Case Study: Pre-Launch access Neuroblastoma

A small pharma company obtained the rights to a drug in the process of development for treating Neuroblastoma. Their primary aim was to apply for approval and then launch it in Europe first, followed by other regions. Nonetheless, there was a significant demand for early access to the drug in Europe and other global markets prior to its launch.

The objective was to ensure access was only provided to eligible patients and that HCPs were given appropriate support to provide a positive experience.

Read the case study to understand how Clinigen provided access to over 130 patients and implemented a sustainable and self-funding program that could be continued for many years where needed.